NCT07502118 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07502118
Title	NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) (NexCAR19)
Acronym	NexCAR19
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Health Institutes of Turkey
Indications	diffuse large B-cell lymphoma follicular lymphoma mantle cell lymphoma marginal zone lymphoma non-Hodgkin lymphoma high-grade B-cell lymphoma double-hit/triple-hit B-cell acute lymphoblastic leukemia B-cell lymphoma primary mediastinal B-cell lymphoma
Therapies	Talicabtagene autoleucel
Age Groups:	adult \| senior
Covered Countries	TUR

Facility	Status	City	Country	Details
Ankara Bilkent City Hospital - Hematology Clinic	RECRUITING	Ankara	Turkey (Türkiye)	Details
Ankara Etlik City Hospital - Hematology Clinic	RECRUITING	Ankara	Turkey (Türkiye)	Details
Hacettepe University Faculty of Medicine - Department of Internal Medicine, Division of Hematology	NOT_YET_RECRUITING	Ankara	Turkey (Türkiye)	Details
University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital	RECRUITING	Ankara	Turkey (Türkiye)	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07502118Clinical Trial Detail